Home
OTLK
OTLK News

Latest Outlook Therapeutics Inc. (OTLK) News on September 10, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

GlobeNewswire

3 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

Pharmaceutical Technology

3 months ago

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

3 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

GlobeNewswire

3 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

GlobeNewswire

4 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

MT Newswires

4 months ago

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire

4 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire

4 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

MT Newswires

5 months ago

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

5 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

GlobeNewswire

6 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

7 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire

7 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

7 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

GlobeNewswire

7 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

GlobeNewswire

8 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

GlobeNewswire

8 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

MT Newswires

8 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

8 months ago

Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Benzinga

8 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

GlobeNewswire

8 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

8 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

GuruFocus.com

8 months ago

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

Outlook Therapeutics Reports 2024 Financial Results

TipRanks

8 months ago

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics provides ONS-5010/LYTENAVA update

TipRanks

8 months ago

Outlook Therapeutics provides ONS-5010/LYTENAVA update

MT Newswires

8 months ago

Outlook Therapeutics' Annual Loss Per Share Narrows in FY24; Shares Up

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

8 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

MT Newswires

9 months ago

Outlook Therapeutics to Cut 23% Workforce to Lower Costs

Outlook Therapeutics® Streamlines Operations

GlobeNewswire

9 months ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

9 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

GlobeNewswire

9 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

MT Newswires

9 months ago

Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

TipRanks

9 months ago

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Zacks

9 months ago

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

Pharmaceutical Technology

9 months ago

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial

Clinical Trials Arena

9 months ago

Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Benzinga

9 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

MT Newswires

9 months ago

Sector Update: Health Care

MT Newswires

9 months ago

Outlook Therapeutics Says Eye Disease Drug Fails Key Trial Endpoint; Shares Plunge

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

GlobeNewswire

9 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Simply Wall St.

9 months ago

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

GlobeNewswire

10 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

GlobeNewswire

a year ago

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

GlobeNewswire

a year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Thomson Reuters StreetEvents

a year ago

Q3 2024 Outlook Therapeutics Inc Earnings Call

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?

Insider Monkey

a year ago

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

GlobeNewswire

a year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

MT Newswires

a year ago

Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%

Simply Wall St.

a year ago

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

MT Newswires

a year ago

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Thomson Reuters StreetEvents

a year ago

Q2 2024 Outlook Therapeutics Inc Earnings Call

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

MT Newswires

a year ago

Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

GlobeNewswire

a year ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Retina World Congress 2024

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Insiders are Piling into These 10 Healthcare Stocks in 2024

Insider Monkey

a year ago

Insiders are Piling into These 10 Healthcare Stocks in 2024

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

7 of the Best Speculative Stocks You Can Snag for Less Than $1

InvestorPlace

2 years ago

7 of the Best Speculative Stocks You Can Snag for Less Than $1

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

InvestorPlace

2 years ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

GuruFocus.com

2 years ago

Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

2 years ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Eos Energy Enterprises Join Forces with SABIC Specialties to Produce a Specialty Light-Weight, Conductive Composite Thermoplastic for Eos Z3TM Battery

GlobeNewswire

2 years ago

Eos Energy Enterprises Join Forces with SABIC Specialties to Produce a Specialty Light-Weight, Conductive Composite Thermoplastic for Eos Z3TM Battery

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

GlobeNewswire

2 years ago

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

Powerfleet and MiX Telematics Announce Shareholders Meetings to Vote on Proposed Business Combination

PR Newswire

2 years ago

Powerfleet and MiX Telematics Announce Shareholders Meetings to Vote on Proposed Business Combination

Here's What We Like About Peoples Bancorp of North Carolina's (NASDAQ:PEBK) Upcoming Dividend

Simply Wall St.

2 years ago

Here's What We Like About Peoples Bancorp of North Carolina's (NASDAQ:PEBK) Upcoming Dividend

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP

PR Newswire

2 years ago

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP

Associated Press Finance

2 years ago

Alerus: Q4 Earnings Snapshot

Alerus Financial Corp (ALRS) Reports Q4 Loss and Balance Sheet Repositioning

GuruFocus.com

2 years ago

Alerus Financial Corp (ALRS) Reports Q4 Loss and Balance Sheet Repositioning

Alerus Financial Corporation Announces Fourth Quarter 2023 Results, Including Balance Sheet Repositioning

Business Wire

2 years ago

Alerus Financial Corporation Announces Fourth Quarter 2023 Results, Including Balance Sheet Repositioning

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

Zacks

2 years ago

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

Aemetis Biogas Expands Revenues with First Sale of Low Carbon Fuel Standard Credits

NewMediaWire

2 years ago

Aemetis Biogas Expands Revenues with First Sale of Low Carbon Fuel Standard Credits

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

GlobeNewswire

2 years ago

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Hear from Ciaran Long, CFO of a.k.a. Brands Live at ICR Conference 2024

IPO-Edge.com

2 years ago

Hear from Ciaran Long, CFO of a.k.a. Brands Live at ICR Conference 2024

FirstSun, HomeStreet to merge

Banking Dive

2 years ago

FirstSun, HomeStreet to merge

HomeStreet to sell itself after tough year

American Banker

2 years ago

HomeStreet to sell itself after tough year

Armada Hoffler To Discuss Fourth Quarter Earnings On February 22nd

GlobeNewswire

2 years ago

Armada Hoffler To Discuss Fourth Quarter Earnings On February 22nd

LuxUrban Hotels to Present at Upcoming Investor Conferences

Business Wire

2 years ago

LuxUrban Hotels to Present at Upcoming Investor Conferences

The 3 Best Biotech Stocks to Buy in January 2024

InvestorPlace

2 years ago

The 3 Best Biotech Stocks to Buy in January 2024

SKYX Will Debut Its New Patented Game-Changing Smart Home Platforms Technologies at CES 2024 - Opening Today, January 9th in Las Vegas

ACCESSWIRE

2 years ago

SKYX Will Debut Its New Patented Game-Changing Smart Home Platforms Technologies at CES 2024 - Opening Today, January 9th in Las Vegas

Qurate CEO Talks Turnaround and Growth Plans

WWD

2 years ago

Qurate CEO Talks Turnaround and Growth Plans

VIZSLA SILVER ANNOUNCES SIGNIFICANT INCREASE IN CONTAINED OUNCES AND INCREASE IN GRADE OF INDICATED CATEGORY TO 551 G/T AGEQ IN UPDATED MINERAL RESOURCES ESTIMATE

CNW Group

2 years ago

VIZSLA SILVER ANNOUNCES SIGNIFICANT INCREASE IN CONTAINED OUNCES AND INCREASE IN GRADE OF INDICATED CATEGORY TO 551 G/T AGEQ IN UPDATED MINERAL RESOURCES ESTIMATE

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

GlobeNewswire

2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Alimera Completes Recruitment for the Synchronicity Study

GlobeNewswire

2 years ago

Alimera Completes Recruitment for the Synchronicity Study

Share on Social Networks: